Akihiro Katayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akihiro Katayama has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Jun Wada
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
4 shared publications Kazuyuki Hida
Department of Diabetology and Endocrinology NHO Okayama Medical Center Okayama Japan
4 shared publicationsJun Eguchi
Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan
3 shared publicationsMasaya Takeda
Department of Diabetology and Endocrinology NHO Okayama Medical Center Okayama Japan
3 shared publications- Mayu Watanabe
Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Okayama, Japan
3 shared publications Yuichi Matsushita
Department of Diabetology and Endocrinology NHO Okayama Medical Center Okayama Japan
3 shared publications
Latest Publications
- Open Access
- 1 September 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (5) , e005114
Perinatal and postpartum insulin secretion capacity in women with early-onset and late-onset gestational diabetes
Introduction: Gestational diabetes mellitus (GDM) is associated with metabolic risks and adverse maternal and fetal perinatal outcomes. This study aimed to compare pregnancy outcomes, postpartum glucose intolerance and insulin secretion capacity in women with early-onset GDM (EGDM, diagnosed<24 weeks) and late GDM (LGDM, diagnosed≥24 weeks) in Japan. Research design and methods: This single-center, retrospective study included 107 women with EGDM and 109 with LGDM. GDM was diagnosed through the 75 g oral glucose tolerance test. Postpartum glucose tolerance was assessed 4–16 weeks post partum. Maternal and neonatal outcomes, insulin secretion, and postpartum glucose tolerance were analyzed and compared. Subgroup analyses were performed for women with and without obesity. Results: Although gestational weight gain was significantly lower in women with EGDM than in those with LGDM, pregnancy outcomes, including neonatal birth weight, small for gestational age and large for gestational age, were comparable between the two groups. However, postpartum glucose intolerance was more prevalent in women with EGDM, particularly in those without obesity who also had significantly lower initial insulin secretion capacity. Insulin resistance was comparable between the groups, suggesting that reduced insulin secretion, rather than insulin resistance, contributes to postpartum glucose intolerance in EGDM. Conclusions: EGDM in women without obesity is associated with a high risk for postpartum glucose intolerance. This could be related to impaired insulin secretion rather than insulin resistance. These findings highlight the need for close monitoring and tailored interventions for patients with EGDM. More research is required to improve diagnostic and management strategies, considering ethnic variations in insulin secretion and glucose tolerance.
- 1 September 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (5) , e005114
Open AccessPerinatal and postpartum insulin secretion capacity in women with early-onset and late-onset gestational diabetes
Introduction: Gestational diabetes mellitus (GDM) is associated with metabolic risks and adverse maternal and fetal perinatal outcomes. This study aimed to compare pregnancy outcomes, postpartum glucose intolerance and insulin secretion capacity in women with early-onset GDM (EGDM, diagnosed<24 weeks) and late GDM (LGDM, diagnosed≥24 weeks) in Japan. Research design and methods: This single-center, retrospective study included 107 women with EGDM and 109 with LGDM. GDM was diagnosed through the 75 g oral glucose tolerance test. Postpartum glucose tolerance was assessed 4–16 weeks post partum. Maternal and neonatal outcomes, insulin secretion, and postpartum glucose tolerance were analyzed and compared. Subgroup analyses were performed for women with and without obesity. Results: Although gestational weight gain was significantly lower in women with EGDM than in those with LGDM, pregnancy outcomes, including neonatal birth weight, small for gestational age and large for gestational age, were comparable between the two groups. However, postpartum glucose intolerance was more prevalent in women with EGDM, particularly in those without obesity who also had significantly lower initial insulin secretion capacity. Insulin resistance was comparable between the groups, suggesting that reduced insulin secretion, rather than insulin resistance, contributes to postpartum glucose intolerance in EGDM. Conclusions: EGDM in women without obesity is associated with a high risk for postpartum glucose intolerance. This could be related to impaired insulin secretion rather than insulin resistance. These findings highlight the need for close monitoring and tailored interventions for patients with EGDM. More research is required to improve diagnostic and management strategies, considering ethnic variations in insulin secretion and glucose tolerance.
- Open Access
- 8 April 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (7) , 1346-1349
Case of type 1 diabetes mellitus with decreased hemoglobin glycation index after switching insulin pump
This case report described a 78‐year‐old woman with type 1 diabetes who experienced a significant decrease in the hemoglobin glycation index (HGI) after switching her insulin pump from MiniMed™770G to 780G. Despite minimal changes in glycemic control, including a slight decrease in the average sensor glucose and % coefficient of variation (%CV) from continuous glucose monitoring metrics, her glycated hemoglobin level decreased from 8.2% to 7.3%, and HGI decreased from approximately 1.3–0.5. Previous reports have shown that HGI indicates differences in the glycation rate of hemoglobin between individuals. Moreover, a high HGI is a risk factor for diabetic complications. However, there are no reports on changes in HGI within an individual. Therefore, the significance of intraindividual HGI changes, as in this case, should be investigated.
- 8 April 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (7) , 1346-1349
Open AccessCase of type 1 diabetes mellitus with decreased hemoglobin glycation index after switching insulin pump
This case report described a 78‐year‐old woman with type 1 diabetes who experienced a significant decrease in the hemoglobin glycation index (HGI) after switching her insulin pump from MiniMed™770G to 780G. Despite minimal changes in glycemic control, including a slight decrease in the average sensor glucose and % coefficient of variation (%CV) from continuous glucose monitoring metrics, her glycated hemoglobin level decreased from 8.2% to 7.3%, and HGI decreased from approximately 1.3–0.5. Previous reports have shown that HGI indicates differences in the glycation rate of hemoglobin between individuals. Moreover, a high HGI is a risk factor for diabetic complications. However, there are no reports on changes in HGI within an individual. Therefore, the significance of intraindividual HGI changes, as in this case, should be investigated.
- Open Access
- 30 May 2024
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 12 (3) , e004237
Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3)
Introduction ACE cleaves angiotensin I (Ang I) to angiotensin II (Ang II) inducing vasoconstriction via Ang II type 1 (AT1) receptor, while ACE2 cleaves Ang II to Ang (1–7) causing vasodilatation by acting on the Mas receptor. In diabetic kidney disease (DKD), it is still unclear whether plasma or urine ACE2 levels predict renal outcomes or not. Research design and methods Among 777 participants with diabetes enrolled in the Urinary biomarker for Continuous And Rapid progression of diabetic nEphropathy study, the 296 patients followed up for 9 years were investigated. Plasma and urinary ACE2 levels were measured by the ELISA. The primary end point was a composite of a decrease of estimated glomerular filtration rate (eGFR) by at least 30% from baseline or initiation of hemodialysis or peritoneal dialysis. The secondary end points were a 30% increase or a 30% decrease in albumin-to-creatinine ratio from baseline to 1 year. Results The cumulative incidence of the renal composite outcome was significantly higher in group 1 with lowest tertile of plasma ACE2 (p=0.040). Group 2 with middle and highest tertile was associated with better renal outcomes in the crude Cox regression model adjusted by age and sex (HR 0.56, 95% CI 0.31 to 0.99, p=0.047). Plasma ACE2 levels demonstrated a significant association with 30% decrease in ACR (OR 1.46, 95% CI 1.044 to 2.035, p=0.027) after adjusting for age, sex, systolic blood pressure, hemoglobin A1c, and eGFR. Conclusions Higher baseline plasma ACE2 levels in DKD were protective for development and progression of albuminuria and associated with fewer renal end points, suggesting plasma ACE2 may be used as a prognosis marker of DKD. Trial registration number UMIN000011525.
- 30 May 2024
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 12 (3) , e004237
Open AccessPlasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3)
Introduction ACE cleaves angiotensin I (Ang I) to angiotensin II (Ang II) inducing vasoconstriction via Ang II type 1 (AT1) receptor, while ACE2 cleaves Ang II to Ang (1–7) causing vasodilatation by acting on the Mas receptor. In diabetic kidney disease (DKD), it is still unclear whether plasma or urine ACE2 levels predict renal outcomes or not. Research design and methods Among 777 participants with diabetes enrolled in the Urinary biomarker for Continuous And Rapid progression of diabetic nEphropathy study, the 296 patients followed up for 9 years were investigated. Plasma and urinary ACE2 levels were measured by the ELISA. The primary end point was a composite of a decrease of estimated glomerular filtration rate (eGFR) by at least 30% from baseline or initiation of hemodialysis or peritoneal dialysis. The secondary end points were a 30% increase or a 30% decrease in albumin-to-creatinine ratio from baseline to 1 year. Results The cumulative incidence of the renal composite outcome was significantly higher in group 1 with lowest tertile of plasma ACE2 (p=0.040). Group 2 with middle and highest tertile was associated with better renal outcomes in the crude Cox regression model adjusted by age and sex (HR 0.56, 95% CI 0.31 to 0.99, p=0.047). Plasma ACE2 levels demonstrated a significant association with 30% decrease in ACR (OR 1.46, 95% CI 1.044 to 2.035, p=0.027) after adjusting for age, sex, systolic blood pressure, hemoglobin A1c, and eGFR. Conclusions Higher baseline plasma ACE2 levels in DKD were protective for development and progression of albuminuria and associated with fewer renal end points, suggesting plasma ACE2 may be used as a prognosis marker of DKD. Trial registration number UMIN000011525.
- Open Access
- 15 November 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (11) , e6572
Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus 3 days after initiating sodium‐glucose cotransporter 2 inhibitor while on an extremely low carbohydrate diet: A case report
This paper presents a case with type 2 diabetes mellitus on a very‐low‐carbohydrate diet who developed euglycemic diabetic ketoacidosis (EDKA) 3 days after starting sodium‐glucose cotransporter 2 inhibitors (SGLT2i). When initiating SGLT2i, healthcare providers should confirm the implementation of a low‐carbohydrate diet and provide intensive guidance to prevent EDKA.
- 15 November 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (11) , e6572
Open AccessEuglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus 3 days after initiating sodium‐glucose cotransporter 2 inhibitor while on an extremely low carbohydrate diet: A case report
This paper presents a case with type 2 diabetes mellitus on a very‐low‐carbohydrate diet who developed euglycemic diabetic ketoacidosis (EDKA) 3 days after starting sodium‐glucose cotransporter 2 inhibitors (SGLT2i). When initiating SGLT2i, healthcare providers should confirm the implementation of a low‐carbohydrate diet and provide intensive guidance to prevent EDKA.
- 18 May 2022
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 16 (10) , 759-770
Analysis of Inflammatory Cytokines and Estimated Glomerular Filtration Rate Decline in Japanese Patients with Diabetic Kidney Disease: A Pilot Study
Background: It is important to identify additional prognostic factors for diabetic kidney disease. Materials & methods: Baseline levels of ten cytokines (APRIL/TNFSF13, BAFF/TNFSF13B, chitinase 3-l...
- 18 May 2022
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 16 (10) , 759-770
Analysis of Inflammatory Cytokines and Estimated Glomerular Filtration Rate Decline in Japanese Patients with Diabetic Kidney Disease: A Pilot Study
Background: It is important to identify additional prognostic factors for diabetic kidney disease. Materials & methods: Baseline levels of ten cytokines (APRIL/TNFSF13, BAFF/TNFSF13B, chitinase 3-l...
- Open Access
- 12 September 2021
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 13 (3) , 588-591
Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
Subcutaneous insulin resistance syndrome is a rare condition that causes difficulty in glycemic control due to severe resistance to subcutaneous insulin injections. We herein present a case of a 40‐year‐old woman with type 2 diabetes mellitus who had been diagnosed with subcutaneous insulin resistance syndrome since the age of 29 years, and had been persistently treated with continuous subcutaneous insulin infusion using a mixture of insulin lispro and heparin. The patient was switched from insulin lispro plus heparin to ultra‐rapid insulin lispro; given that it contains treprostinil and citrate, it is expected to have similar effects as heparin, and shows similar glucose‐lowering effects and insulin absorption. Our results suggest that treatment with ultra‐rapid insulin lispro is effective for subcutaneous insulin resistance syndrome.
- 12 September 2021
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 13 (3) , 588-591
Open AccessCase of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
Subcutaneous insulin resistance syndrome is a rare condition that causes difficulty in glycemic control due to severe resistance to subcutaneous insulin injections. We herein present a case of a 40‐year‐old woman with type 2 diabetes mellitus who had been diagnosed with subcutaneous insulin resistance syndrome since the age of 29 years, and had been persistently treated with continuous subcutaneous insulin infusion using a mixture of insulin lispro and heparin. The patient was switched from insulin lispro plus heparin to ultra‐rapid insulin lispro; given that it contains treprostinil and citrate, it is expected to have similar effects as heparin, and shows similar glucose‐lowering effects and insulin absorption. Our results suggest that treatment with ultra‐rapid insulin lispro is effective for subcutaneous insulin resistance syndrome.
- Open Access
- 7 September 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (9) , e04574
Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes mellitus: A report of two cases
Immune checkpoint inhibitor‐induced diabetes mellitus is a rare immune‐related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes.
- 7 September 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (9) , e04574
Open AccessLongitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes mellitus: A report of two cases
Immune checkpoint inhibitor‐induced diabetes mellitus is a rare immune‐related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes.
- 16 September 2019
- Published by Springer Nature in Diabetology International
- Vol. 11 (2) , 97-104
The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study
Aims/introduction The predictive low glucose management (PLGM) system was introduced in March 2018 in Japan. Although there are some reports demonstrating the benefit of PLGM in preventing hypoglycemia, no data are currently available in Japanese patients with type 1 diabetes mellitus (T1DM). The aim of the present study is to evaluate the effect of PLGM with sensor-augmented pump therapy in the prevention of hypoglycemia in Japanese patients. Materials and methods We included 16 patients with T1DM who used the MiniMed®640G system after switching from the MiniMed®620G system. We retrospectively analysed the data of the continuous glucose monitoring system in 1 month after switching to MiniMed®640G. Results The area under the curve (AUC) of hypoglycemia of < 70 mg/dL was lowered from 0.42 ± 0.43 mg/dL day to 0.18 ± 0.18 mg/dL day (P = 0.012). Correspondingly, the duration of severe hypoglycemia (< 54 mg/dL) was reduced significantly from 15.3 ± 21.7 min/day to 4.8 ± 6.9 min/day (P = 0.019). The duration of hypoglycemia was reduced, but the reduction was not significant. Regarding the AUC for hyperglycemia > 180 mg/dL and the duration of hyperglycemia did not change. With the PLGM function, 79.3% of the predicted hypoglycemic events were avoided. Conclusions The hypoglycemia avoidance rate was comparable to those in previous reports. In addition, we demonstrated that PLGM can markedly suppress severe hypoglycemia without deteriorating glycemic control in Japanese T1DM patients. It is necessary to further investigate the effective use of the PLGM feature such as establishing a lower limit and the timing of resumption.
- 16 September 2019
- Published by Springer Nature in Diabetology International
- Vol. 11 (2) , 97-104
The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study
Aims/introduction The predictive low glucose management (PLGM) system was introduced in March 2018 in Japan. Although there are some reports demonstrating the benefit of PLGM in preventing hypoglycemia, no data are currently available in Japanese patients with type 1 diabetes mellitus (T1DM). The aim of the present study is to evaluate the effect of PLGM with sensor-augmented pump therapy in the prevention of hypoglycemia in Japanese patients. Materials and methods We included 16 patients with T1DM who used the MiniMed®640G system after switching from the MiniMed®620G system. We retrospectively analysed the data of the continuous glucose monitoring system in 1 month after switching to MiniMed®640G. Results The area under the curve (AUC) of hypoglycemia of < 70 mg/dL was lowered from 0.42 ± 0.43 mg/dL day to 0.18 ± 0.18 mg/dL day (P = 0.012). Correspondingly, the duration of severe hypoglycemia (< 54 mg/dL) was reduced significantly from 15.3 ± 21.7 min/day to 4.8 ± 6.9 min/day (P = 0.019). The duration of hypoglycemia was reduced, but the reduction was not significant. Regarding the AUC for hyperglycemia > 180 mg/dL and the duration of hyperglycemia did not change. With the PLGM function, 79.3% of the predicted hypoglycemic events were avoided. Conclusions The hypoglycemia avoidance rate was comparable to those in previous reports. In addition, we demonstrated that PLGM can markedly suppress severe hypoglycemia without deteriorating glycemic control in Japanese T1DM patients. It is necessary to further investigate the effective use of the PLGM feature such as establishing a lower limit and the timing of resumption.